A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Moderate to severe active RA of ≥6 months duration
DAS28 \>3.2
Inadequate response to a stable dose of non-biologic DMARD for ≥2 months
Those receiving oral corticosteroids must have been at stable dose for ≥25 days in the 28 days prior to first study treatment
You may not be if
Rheumatic autoimmune disease other than RA
History of or current inflammatory joint disease other than RA
Previous treatment with alkylating agents or total lymphoid irradiation
Intra-articular or parenteral corticosteroids within 6 weeks prior to Baseline
Previous treatment with any cell-depleting therapies
American College of Rheumatology (ACR) Functional Class IV
Clareo Health | A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs
